Abstract
Objective: We conducted a systematic review of the literature aiming to identify original studies that have evaluated the effect of genes on the response to medications used to treat psychiatric disorders in children and adolescents. Results: We included 35 original studies on the pharmacogenetics of childhood psychiatric disorders. Thirty-three studies addressed the association between genes, particularly dopamine transporter gene (DAT1) and dopamine D4 receptor gene (DRD4), and response to medication for the treatment of attention-deficit/hyperactivity disorder (ADHD). Only two studies investigated atomoxetine as the pharmacological intervention, and the other 31 studies investigated methylphenidate (MPH). One study assessed children with depression and anxiety disorders and another assessed children with autism; in both of them selective serotonin reuptake inhibitors (SSRIs) were the pharmacological intervention. Conclusion: The existing literature on the pharmacogenetics of ADHD suggests that response to MPH is influenced by several different polymorphisms, each one exerting a small effect. Genome-wide association studies and multi-center collaborative projects are likely to overcome the barriers for the development of the field. Future investigations should evaluate, besides improvement of symptoms, emergence of clinically relevant side effects. The lessons we have learned from the progress of the pharmacogenetics of ADHD can be relevant for developing pharmacogenetic studies in other child and adolescent psychiatric disorders.
Keywords: Atomoxetine, childhood mental disorders, pharmacogenetics, pharmacogenomics, ADHD, depression, autism, methylphenidate, selective serotonin reuptake inhibitor
Current Pharmaceutical Design
Title: Pharmacogenetic Approach for a Better Drug Treatment in Children
Volume: 16 Issue: 22
Author(s): Guilherme Polanczyk, Marcelo P. Bigarella, Mara H. Hutz and Luis Augusto Rohde
Affiliation:
Keywords: Atomoxetine, childhood mental disorders, pharmacogenetics, pharmacogenomics, ADHD, depression, autism, methylphenidate, selective serotonin reuptake inhibitor
Abstract: Objective: We conducted a systematic review of the literature aiming to identify original studies that have evaluated the effect of genes on the response to medications used to treat psychiatric disorders in children and adolescents. Results: We included 35 original studies on the pharmacogenetics of childhood psychiatric disorders. Thirty-three studies addressed the association between genes, particularly dopamine transporter gene (DAT1) and dopamine D4 receptor gene (DRD4), and response to medication for the treatment of attention-deficit/hyperactivity disorder (ADHD). Only two studies investigated atomoxetine as the pharmacological intervention, and the other 31 studies investigated methylphenidate (MPH). One study assessed children with depression and anxiety disorders and another assessed children with autism; in both of them selective serotonin reuptake inhibitors (SSRIs) were the pharmacological intervention. Conclusion: The existing literature on the pharmacogenetics of ADHD suggests that response to MPH is influenced by several different polymorphisms, each one exerting a small effect. Genome-wide association studies and multi-center collaborative projects are likely to overcome the barriers for the development of the field. Future investigations should evaluate, besides improvement of symptoms, emergence of clinically relevant side effects. The lessons we have learned from the progress of the pharmacogenetics of ADHD can be relevant for developing pharmacogenetic studies in other child and adolescent psychiatric disorders.
Export Options
About this article
Cite this article as:
Polanczyk Guilherme, P. Bigarella Marcelo, H. Hutz Mara and Augusto Rohde Luis, Pharmacogenetic Approach for a Better Drug Treatment in Children, Current Pharmaceutical Design 2010; 16 (22) . https://dx.doi.org/10.2174/138161210791959872
DOI https://dx.doi.org/10.2174/138161210791959872 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of a Child Psychopharmacology Trial Scale
Current Psychopharmacology Medicinal Chemistry of Potassium Channel Modulators: An Update of Recent Progress (2011-2017)
Current Medicinal Chemistry Effects of the Disease Characteristics and the Treatment on Psychological Status in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Current Rheumatology Reviews Physiological Role of Peroxisome Proliferator-Activated Receptors Type Alpha on Dopamine Systems
CNS & Neurological Disorders - Drug Targets The Association of MME microRNA Binding Site Polymorphism with the Risk of Late Onset Alzheimer’s Disease in Northern Han Chinese
Current Neurovascular Research Hybrids of Coumarin Derivatives as Potent and Multifunctional Bioactive Agents: A Review
Medicinal Chemistry Glia-Driven Neuroinflammation and Systemic Inflammation in Alzheimer’s Disease
Current Neuropharmacology Differences in Post-ischemic Motor Recovery and Angiogenesis of MCAO Rats Following Electroacupuncture at Different Acupoints
Current Neurovascular Research Cannabinoids: Occurrence and Medicinal Chemistry
Current Medicinal Chemistry Tumour Necrosis Factor α Gene Promoter and its Role in Rheumatoid Arthritis Outcome and Pharmacogenetics
Current Pharmacogenomics β-Synuclein Assembly as a Therapeutic Target of Parkinsons Disease and Related Disorders
Current Pharmaceutical Design Stretch, Shrink, and Shatter the Rhythms: The Intrinsic Circadian Period in Mania and Depression
CNS & Neurological Disorders - Drug Targets How Valid is Placebo in the Indian Setting?
Central Nervous System Agents in Medicinal Chemistry Bi-3-Azaoxoisoaporphine Derivatives have Antidepressive Properties in a Murine Model of Post Stroke-Depressive Like Behavior
Current Neurovascular Research QSPR and Flow Cytometry Analysis (QSPR-FCA): Review and New Findings on Parallel Study of Multiple Interactions of Chemical Compounds with Immune Cellular and Molecular Targets
Current Drug Metabolism Role of Molecular Hydrogen in Skin Diseases and its Impact in Beauty
Current Pharmaceutical Design Drug Tissue Distribution: Study Methods and Therapeutic Implications
Current Pharmaceutical Design Nanoparticles, Promising Carriers in Drug Targeting: A Review
Current Drug Therapy 5-(4-(2-[ F]fluoroethoxy)phenyl)-1-(2,4-dichlorophenyl)-4-cyano-N- (piperidin-1-yl)-1H-pyrazole-3-carboxamide ([ F]JHU88868), a Novel Radioligand for PET Imaging of Cannabinoid Type 1 Receptors
Current Radiopharmaceuticals MiR-106a Associated with Diabetic Peripheral Neuropathy Through the Regulation of 12/15-LOX-meidiated Oxidative/Nitrative Stress
Current Neurovascular Research